What will impede the growth of the PCOS market?

Lack of standard diagnostic criteria, and treatment adherence were some of the issues cited. 

A recent report by DelveInsight Business Research, LLP said developments such as the emergence of new therapies, and the growing emphasis on personalised medicine and tailored treatment have been helping treat women with Polycystic Ovarian Syndrome (PCOS).

Despite such, the PCOS market will still face some challenges that will delay its growth.

DelveInsight said one of the major challenges is the lack of standardised diagnostic criteria, which can lead to underdiagnosis or misdiagnosis, thus limiting the potential market size. 

Treatment adherence is another concern since PCOS often requires long-term management strategies that patients may find difficult to maintain.

DelveInsight said there is also a need for more comprehensive and effective treatment options. It noted that current therapies focus on symptom management rather than addressing the underlying causes of the syndrome. 

Treating PCOS also poses an economic burden and disrupts patients’ well-being and quality of life. 

The growth of the PCOS market “may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists,” DelveInsight said.

“In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the polycystic ovarian syndrome market growth,” it added.